



Financial Tear Sheet

Corporate Profile

MyoKardia is a clinical stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. MyoKardia's initial focus is on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. MyoKardia has used its precision medicine platform to generate a pipeline of therapeutic programs for the chronic treatment of the two most prevalent forms of heritable cardiomyopathy —hypertrophic cardiomyopathy, or HCM, and dilated cardiomyopathy, or DCM.

Stock Information

MYOK (Common Stock)

Exchange	NASDAQ GS (US Dollar)
Price	\$12.70
Change (%)	▼ 0.2 (1.55%)
Volume	64,809
52 Week Low	\$10.55
Market Cap	\$399,489,854
Rolling EPS	-0.63
PE Ratio	0
Shares Outstanding	31,455,894

Data as of 05/26/17 4:00 p.m. ET



Recent Press Releases

05/09/17

MyoKardia Reports First Quarter 2017 Financial Results and Operational Progress

05/02/17

MyoKardia to Announce First Quarter 2017 Financial Results and Host Conference Call on Tuesday, May 9, 2017

04/18/17









MyoKardia Appoints David Meeker, M.D., to Board of Directors













Upcoming Events

There are currently no events scheduled.

SEC Filings

<< First | Previous | Next | Last >>

Filing Date	Form	Description	Filing Group	Downloads
05/16/17	4	Statement of changes in beneficial ownership of securities	3,4,5	   
05/16/17	4	Statement of changes in beneficial ownership of securities	3,4,5	   
05/16/17	4	Statement of changes in beneficial ownership of securities	3,4,5	   
05/09/17	10-Q	Quarterly report which provides a continuing view of a company's financial position	Quarterly Filings	   
05/09/17	8-K	Report of unscheduled material events or corporate event	Current Reports	   
04/25/17	DEFA14A	Additional proxy soliciting materials - definitive	Proxy Filings	   
04/25/17	DEF 14A	Official notification to shareholders of matters to be brought to a vote ("Proxy")	Proxy Filings	   

04/19/17	4	Statement of changes in beneficial ownership of securities	3,4,5	   
04/19/17	3	Initial filing by director officer or owner of more than ten percent.	3,4,5	   
04/18/17	8-K	Report of unscheduled material events or corporate event	Current Reports	   

<< First | Previous | Next | Last >>

Corporate Governance

Tassos Gianakakos Chief Executive Officer

Jonathan Fox, M.D., Ph.D. Chief Medical Officer

Jake Bauer Vice President, Business Development and Business Operations

Ingrid Boyes Senior Vice President, Human Resources

Steven Chan Vice President, Corporate Controller

Joseph Lambing, Ph.D. Senior Vice President, Nonclinical and Pharmaceutical Development

Robert McDowell Senior Vice President of Drug Discovery

Iris Roth, Ph.D. Vice President, Program Team Leader